We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 354

NASDAQ Biotechnology Index surpasses all-time high in 1Q13

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 16 2013

The NASDAQ Biotechnology Index reportedly rose in the first quarter of 2013 (1Q13) above levels last seen during the 2000 genomics bubble peakthe

U.S. intervenes in False Claims Act suit against biotech company

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • April 4 2013

The U.S. government has intervened in part of a False Claims Act (FCA) lawsuit against Agave BioSystems, a biotechnology-based small business with

Biotech secures $5.3 million for immunosuppressant drug research

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • April 18 2013

San Francisco-based startup, Nurix, Inc., which reportedly develops T-cellspecific immunosuppressants used to treat autoimmune diseases such as

VC, private financing still hard to find for OmicsMDx firms

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • April 18 2013

Companies developing diagnostics (MDx) and "omics" technologies (e.g., genomics, epigenomics, proteomics, metabolomics), used as predictors of

Syros Pharmaceuticals raises $30 million for cancer research

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • April 18 2013

Newly launched life sciences company, Syros Pharmaceuticals, has announced a $30 million Series A financing round led by company co-founders Arch

Sequestration impact on FDA uncertain

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • March 7 2013

Speaking during the Generic Pharmaceutical Association's annual conference in February 2013, Food and Drug Administration (FDA) Commissioner Margaret

Biotech grants totaling $1 billion awarded to almost 3,000 companies

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • November 18 2010

The U.S. Qualifying Therapeutic Discovery Project Program has recently identified the biotech companies that will receive part of $1 billion in tax credits or grants under the Affordable Care Act to stimulate research and development

Stakeholders provide input on FDA review standards for biosimilars

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • November 18 2010

The Food and Drug Administration (FDA) recently conducted a two-day hearing to begin the process of determining how it will go about creating review standards for the generic copies (biosimilars) of prescription drugs developed from biological materials (biologics

Pharma merger activity attributed to “patent cliff”

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • November 18 2010

Noting that many of the pharmaceutical industry's best-selling products will soon lose their patent protection, industry analysts have reportedly suggested that the potential loss of nearly one-third of industry revenues in the near term could account for recent merger activity among the world's largest pharmaceutical companies

Appeals Court considers federal funding of stem cell research

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • December 16 2010

A D.C. Circuit Court of Appeals panel recently heard argument on whether new National Institutes of Health (NIH) guidelines pertaining to federal funding of embryonic stem-cell research violate a law that places certain restrictions on such research